PDC*lung01
Phase 2Biologic
PDC*lung01 is one of 42 biologic programs targeting Immunogenicity. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
87 competitors in Immunogenicity
#DrugCompanyPhaseTrials
1Perjeta
RochePhase 3
Rabies Vaccine
NovartisPhase 3
Prolia
OOrganon and Co
Phase 3
HPV Vaccine
SShanghai Zerun Biotechnology Co.,Ltd
Phase 3
Gardasil-9
BBeijing Health Guard Biotechnology, Inc
Phase 3
Rsvpref
PfizerPhase 3
Bexsero
GSKPhase 3
Gardasil
Merck & Co.Phase 3
PCV21
SanofiPhase 3
Opfolda
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PDC*lung01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- PPDC*line Pharma SAS